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To the Editor:
Thank you for your interest [1] in our experience [2] using
tocilizumab (TCZ) in critically ill patients with coronavirus
2019 (COVID-19). As you rightly pointed out, optimum
timing of the drug’s administration is critical for the mortality beneﬁt that may come from use of the IL-6 antagonists (IL-6a). It is worth noting that in the REMAP-CAP trial
[3] which reported mortality beneﬁt from IL-6a, patients
were enrolled and randomized to receive the agent within
24 h of ICU admission and at a median of 1.4 days (IQR,
0.8–2.8) of hospital admission. Patients enrolled in the
RECOVERY trial received TCZ within a median of two days
from hospitalization [4]. Even with this timely administration, the beneﬁt of reduced progression to invasive mechanical ventilation (IMV), death, and cardiovascular
support was greatest amongst the ones who were on high
ﬂow nasal canula (HFNC) and noninvasive ventilation (NIV).
In a recent prospective meta-analysis [5] based on 10,930
patients hospitalized for COVID-19 from 27 randomized clinical trials, administration of IL-6a was associated with lower
all-cause mortality 28 days after randomization. The association of IL-6a with lower 28-day all-cause mortality was more
marked among patients who were not on IMV at randomization. Once again, the beneﬁts of IL-6 receptor blockers were
most evident among patients who received respiratory support with oxygen by nasal cannula, face mask, HFNC (OR for
death, 0.81 [95% CI 0.67–0.98]), or NIV (OR 0.83 [95% CI
0.72–0.96]) vs. those who required IMV (OR 0.95 [95% CI
0.78–1.16]). There was no clear beneﬁt associated with IL-6
blockade for reducing 90-day mortality or the duration of IMV
among patients who were already on a IMV at the time of
randomization [5, 6]. Additionally, beneﬁt was more marked
when patients were already on corticosteroids at the time of
randomization for TCZ [3–5].
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Our TCZ experience [2] was from early in the pandemic
(March–May 2020) when the drug was non-formulary, in
short supply, and of unproven beneﬁt. Its use was
restricted per system guidelines for critically ill patients.
All of our patients (100%) received corticosteroids. Our
data shows the real-world experience in predominantly mechanically ventilated patients (87%) who received the medication at a mean of 12.6 days from illness onset and at day 6
after admission. TCZ use in our hospital system is now based
on the NIH [7] and IDSA guidelines [8]. It is administered (at
8 mg per kg of actual body weight with a maximum dose of
800 mg IV) early after admission to patients who have rapidly
escalating O2 requirements, elevated CRP, other markers
of inﬂammation, or soon after admission in patients who
require HFNC or ventilatory support in absence of active
bacterial infection. Our experience [2] highlights that TCZ
offered no survival advantage at day 30 in our cohort when it
was used late in mechanically ventilated patients with acute
respiratory distress syndrome (ARDS) from COVID-19.
We outlined in the limitations section that 90% of the
patients who received TCZ in our study [2] had severe disease with respiratory failure requiring IMV before TCZ was
given; therefore, we could not assess the potential beneﬁt
of TCZ in preventing disease progression in patients with
less severe disease. More studies are needed to show
beneﬁt, if any, from TCZ use in mechanically ventilated
patients with COVID-19 ARDS.
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